Reaction
Immune-Mediated Myasthenia Gravis reporting signals
As of the last recalculation, Immune-Mediated Myasthenia Gravis appears in 301 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 168.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 139 | 168.9 | 169.1 |
| Nivolumab | 118 | 138.2 | 138.4 |
| Ipilimumab | 55 | 107.6 | 107.7 |
| Durvalumab | 16 | 57.4 | 57.4 |
| Lenvatinib | 18 | 40.3 | 40.3 |